Employment Agreement - BioMedicines Inc. and Peter J. Langecker
BIOMEDICINES, INC.
3 September 1999
PERSONAL AND CONFIDENTIAL
Peter J. Langecker, M.D., Ph.D.
17610 Via Sereno
Monte Sereno, CA 95030
Tel. 408.354.9661
Fax. 408.354.4414
Dear Doctor Langecker:
On behalf of the Board of Directors of BioMedicines, Inc. (the "Company"), I
would like to offer you the position of Chief Medical Officer and Vice President
Clinical Affairs. In these capacities you will report to me.
In your role as Chief Medical Officer and Vice President Clinical Affairs, you
will have principal responsibility for:
- planning and directing the clinical development of all Company projects
- supervising the Biometrics Group - Dennis Blanchett, M.D., Executive
Director of Biometrics, shall report to you in this capacity
- establishing a clinical development infrastructure that is both
cost-effective and appropriate to the Company's needs at any given time
- selecting and managing external vendors for those projects whose clinical
aspects are performed in whole or in part externally
- evaluating potential product acquisitions for the Company
- participating in partnering discussions, for in- or out-licensing
- contributing to safety management practices and activities for the Company
- helping to ensure compliance with good scientific practices in all areas
for which you are responsible or to which you may contribute
- the hiring and subsequent management of personnel in your groups
- accurate and timely budgetary planning and execution
In your role as Vice President you will also be a member of the Company's Senior
Management Team with joint responsibility for recommending Company strategy to
the Board as well as setting Company policies.
The Board has also directed me to indicate to you its particular desire that you
will contribute creatively, constructively and cordially to the success of your
colleagues and fellow members of the Senior Management Team. I share this view
regarding the importance of such cooperative activities and would indicate that
the Board also believes that all Company officers should be evaluated on the
basis of both individual and cooperative achievement.
This letter will serve to confirm the terms of your employment with
BioMedicines, such employment to begin on 15 October, 1999, or sooner by mutual
agreement. If the terms
<PAGE>
Peter J. Langecker, M.D., Ph.D.
3 September 1999
Page 2
discussed below are acceptable to you, please sign this confirmation letter
where indicated and return it to me, retaining a copy for your records.
1. COMPENSATION.
(a) SALARY, AND EXPENSE REIMBURSEMENTS. You will be paid a monthly salary
of $19,250.00. You will be eligible for a cash bonus of up to twenty percent
(20%) of your base pay. Changes in base pay or the payment of bonuses are made
at the discretion of the Board upon receipt of recommendations from the
Compensation Committee. Currently, salary payments are made twice a month. In
addition, all reasonable business expenses will be reimbursed so long as they
are incurred in the ordinary course of business and consistent with the
then-applicable Company policies.
(b) STOCK OPTIONS. It will be recommended that you receive an option to
purchase up to one hundred thirty thousand (130,000) shares of common stock,
such number and related purchase price to be approved by the Board of Directors
at the sole discretion of the Board. Such approval is not automatic.
It is anticipated that eighty thousand (80,000) shares of this grant, if
approved, will vest at the rate of approximately 2.083% per month (i.e., 25% per
year), subject to the condition that vesting for the first 12 months will occur
only after you have satisfactorily completed 12 months of employment (i.e.,
options on 20,000 shares will vest only on the first anniversary of your
employment). Thereafter, vesting will occur monthly as noted above. Options on
these eighty thousand shares shall be identified as "time-based options."
It is anticipated that up to fifty (50,000) thousand shares will become eligible
for vesting according to the following general schedule*:
- substantive contribution to a successful United States (U.S.)
Investigational New Drug Application (IND) filing defined as regulatory
approval to begin clinical testing - 5,000 shares
- substantive contribution to drug development such that the Board approves
the initiation of phase III testing in the United States - 5,000 shares
- substantive contribution to the acceptance of a U.S. New Drug Application
(NDA) for filing - 15,000 shares
- substantive contribution to the approval of a U.S. NDA - 20,000 shares
- inventing a new use for a product such that a new patent application is
filed in the United States and assigned to Company - 10,000 shares
- co-inventing with another Company employee a new use for a product such
that a new patent application is filed in the United States and assigned to
Company - 5,000 shares
- identifying a new product licensing opportunity and then contributing
substantially to the inlicensing of said product into the Company's
portfolio - 25,000 shares
Options on these fifty thousand shares shall be identified as "event-based
options."
<PAGE>
Peter J. Langecker, M.D., Ph.D.
3 September 1999
Page 3
*- Upon achievement of the goals stated above, vesting shall be made retroactive
to the date of your initial full-time employment with the Company.
The strike price of both the time-based and event-based options shall be $0.225
per share.
In the event that, outside the U.S., the equivalent of a U.S. IND is filed,
phase III testing begins, a marketing application is filed or approved, then 50%
of the number of shares identified above shall become eligible for vesting with
the remaining 50% becoming eligible when the related event occurs in the U.S.
Other terms, or terms that become applicable after the date of this letter, will
appear either in the BioMedicines Stock Option Plan of which you will receive a
copy in the event you accept this offer or in a separate communication to you
from the Company.
Please note that in the event of a stock split or "reverse split" the number of
options and the option price may be adjusted.
Under certain circumstances you may be eligible for acceleration of vesting of
your time-based options. These circumstances and the amount of acceleration are:
1) accelerated vesting in fifty percent (50%) of as yet unvested time-based
options in the event of a merger or acquisition of the Company where control of
the Company changes and you continue to be employed in a substantially similar
capacity after the merger or acquisition 2) accelerated vesting in 100% of your
unvested time-based shares in the event that you are not offered continued
employment in a substantially similar capacity after the merger or acquisition.
Such acceleration, however, remains at the sole discretion of the Board.
Subject to the sole discretion of the Board, you may also be eligible to receive
additional options from time to time during your continued satisfactory
employment with the Company. In this event, the number of options and any
conditions of the grant(s) shall be communicated to you.
(c) HEALTH BENEFITS. Health insurance coverage for you will be provided
under the Company's group health plan. You will be entitled to all health and
medical benefits as are provided to other employees. In addition, you will be
entitled to participate in the Company's 401k plan and all other sponsored
employee benefit plans as and when they are adopted by BioMedicines.
(d) VACATION, HOLIDAYS AND SICK LEAVE. You will receive three (3) weeks of
paid vacation per year as described in the Company's Policy Manual. You are
encouraged to plan for and to take, under appropriate circumstances, the
vacation time to which you are entitled. Sick leave and holidays will be
provided in accordance with the Company's policies, which will be announced from
time to time.
(e) OTHER COMPENSATION MATTERS. In the event that you relocate from your
current residence to a home that is both more than thirty-five miles distant
from your current residence and nearer to the Company premises, you will be
eligible to receive a one-time payment of
<PAGE>
Peter J. Langecker, M.D., Ph.D.
3 September 1999
Page 4
fifteen thousand dollars ($15,000), which may be utilized at your discretion to
assist with the cost of relocation.
In addition, the company will provide to you on a one-time basis a loan of up to
three hundred thousand dollars ($300,000) with a term of five years and at an
interest rate of the prevailing rate for fixed-rate, first mortgages at the time
of the loan. Payments on the loan shall be due monthly. However, each interest
payment shall be forgiven when due subject to continued satisfactory employment
with the Company. If at the end of five years you remain an employee of the
Company, then the Company will agree to extend the loan for an additional three
years, again subject to continuous satisfactory employment. The loan shall be
secured with a second mortgage on the property that you may choose to acquire.
Only the original first mortgage may be senior to this second mortgage held by
the Company and the sum of the first mortgage and this loan may not exceed the
purchase price of the residence purchased with the loan. Moreover, subject to
continued satisfactory employment with the Company, the principal of the loan
shall be forgiven at the anniversary of the loan as follows:
year 1 - ten thousand dollars ($10,000);
year 2 - twenty thousand dollars ($20,000);
year 3 - thirty thousand dollars ($30,000);
year 4 - forty thousand dollars ($40,000).
The maximal total forgiveness shall, therefore, be one hundred thousand dollars
($100,000).
The unpaid principal balance shall be due and payable
- sixty (60 days) of the date you voluntarily cease to be a full-time
employee of the Company or are dismissed for cause
- upon the sale of the property on which the second mortgage is held by the
Company
- or in the event that you declare personal bankruptcy.
In addition, you will agree to prepay a portion of the loan with up to thirty
percent (30%) of the proceeds from the sale of any Company stock.
The note on the property shall be generally consistent with the terms of the
this paragraph (e) but shall, however, be the definitive agreement regarding the
terms of the loan and its repayment.
However, should you choose not to accept all of or part of this loan, then you
shall be eligible to receive a one-time cash payment of up to thirty thousand
dollars, adjusted pro rata, for the amount of the loan not accepted.
2. TERMINATION. You or the Company may terminate the employment relationship
at any time, for any reason, with or without good cause.
3. NON-COMPETE REQUIREMENTS AND OUTSIDE ACTIVITIES. You agree that, while
serving as an employee of the Company, you will not engage in any activity which
is competitive with the Company and will give your sole and only loyalty to the
Company. It is understood that buying
<PAGE>
Peter J. Langecker, M.D., Ph.D.
3 September 1999
Page 5
and selling of securities of any public company does not constitute a violation
of this agreement. An investment in a private company other than, or not
affiliated with, the Company may be construed as a violation of this non-compete
clause unless you have received the prior approval of the Board of Directors or
Chief Executive Officer of the Company, as appropriate. It is understood that
any reasonable obligations that you may have to assist or cooperate with a
previous employer in legal proceedings, in the issuance of patents or
prosecution of patent applications, or in compliance with requests from
governmental authorities do not constitute violations of this agreement,
provided that these obligations are not fulfilled on Company time and do not
adversely impact in a material way the performance of your current duties to the
Company.
You may also serve as a Director in another company with the prior approval of
the Chief Executive Officer again provided that such directorial obligations are
not fulfilled on Company time and do not adversely impact in a material way the
performance of your duties to the Company.
4. PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT. Your acceptance of this
offer is contingent upon the execution of the Company's Proprietary Information
and inventions Agreements, copies of which are enclosed for your review and
execution.
5. ARBITRATION. Any controversy between the parties hereto involving the
construction or application of any terms, covenants or conditions of this
Agreement, or any claims arising out of or relating to this Agreement or the
breach thereof or with your employment with the Company or any termination of
that employment, except with respect to prejudgment remedies, will be submitted
to and settled by final and binding arbitration in San Francisco, California, in
accordance with the Model Employment Dispute Resolution Rules of the American
Arbitration Association (the "Rules") then in effect, any arbitrator shall be
selected pursuant to such Rules and judgment upon the award rendered by the
arbitrators may be entered in any court having jurisdiction thereof.
Please note that the offer is conditional until proof of eligibility for
employment in California according to all applicable local, state, and federal
laws.
To accept this offer, please sign in the space below within seven (7) days of
the date of this offer, indicating your acceptance and agreement to the terms
contained herein. No amendment or modification of the terms of this letter will
be valid unless made in writing and signed by you and an authorized officer of
the Company.
<PAGE>
Peter J. Langecker, M.D., Ph.D.
3 September 1999
Page 6
Peter, on a personal note, I have found our several discussions to be both
congenial and thought-provoking and I know that the Board members whom you have
met feel the same. It is my hope that you will accept this offer and take a
leading role in the management of BioMedicines.
Yours, sincerely
Mark Moran, M.D.
Chief Executive Officer
Accepted by:
/s/ Peter J. Langecker, M.D.
-------------------------------
Peter J. Langecker, M.D., Ph.D.
September 4, 1999
-------------------------------
Date
<PAGE>
Peter J. Langecker, M.D., Ph.D.
3 September 1999
Page 7
PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT
3 September, 1999
BioMedicines, Inc.
1301 Marina Village Parkway Suite 200
Alameda, CA 94501
Gentlemen:
The following confirms an agreement between me and BioMedicines, Inc., a
Delaware corporation (the "Company," which term includes the Company's
subsidiaries, successors and assigns), which is a material part of the
consideration for my employment by the Company:
1. "Proprietary Information" is information that was or is developed by,
became or becomes known by, or was or is assigned or otherwise conveyed to the
Company, and which has commercial value in the Company's business. Proprietary
Information includes, without limitation, trade secrets, financial information,
product plans, customer lists, marketing plans and strategies, forecasts and
other business information, improvements, inventions, business strategies,
formulas, product ideas, works of authorship, processes, copyrightable or
patentable material, schematics, biological material (including cell lines,
antibodies, c-DNAs, antisense nucleotides, proteins, vectors, new chemical
entities, media, reagents and related materials) and techniques for their
handling and use, computer programs, algorithms, techniques, schematics,
know-how and data, and any other confidential or proprietary information of the
Company or its customers or clients which I have been, or may be exposed to, or
have learned or may learn of from time to time in connection with or as a result
of my capacity as a consultant to the Company or during the term of this
Agreement. Proprietary Information shall not include information that is through
no improper action or inaction by me, generally available to the public. I
understand that my employment creates a relationship of confidence and trust
between me and the Company with respect to Proprietary Information of the
Company or its customers which may be learned by me during the period of my
employment.
2. In consideration of my employment by the Company and the compensation
received by me from the Company from time to time, I hereby agree as follows:
(a) All Proprietary Information and all patents, copyrights, trade secret
rights, and other rights (including throughout, without limitation, any
extensions, renewals, continuations or divisions of any of the foregoing) in
connection therewith shall be the sole property of the Company. I hereby assign
to the Company any rights I may have or acquire in such Proprietary Information.
At all times, both during my employment by the Company and after its
termination, I will keep in confidence and trust and will not use or disclose
any Proprietary Information or anything relating to it without the written
consent of the Company, except as may be necessary in the ordinary course of
performing my duties to the Company.
<PAGE>
Peter J. Langecker, M.D., Ph.D.
3 September 1999
Page 8
(b) In the event of the termination of my employment by me or by the
Company for any reason, I shall return all documents, records, apparatus,
equipment and other physical property, or any reproduction of such property,
whether or not pertaining to Proprietary Information, furnished to me by the
Company or produced by myself or others in connection with my employment, to the
Company immediately as and when requested by the Company.
(c) I will promptly disclose to the Company, or any persons designated by
it, all "Inventions," which includes all improvements, inventions, formulas,
ideas, works of authorship, processes, computer programs, algorithms,
techniques, schematics, know-how and data, whether or not patentable, made or
conceived or reduced to practice or developed by me, either alone or jointly
with others, during the term of my employment and for three (3) months
thereafter. To the extent the Company does not have rights therein hereunder,
such disclosure shall be received by the Company in confidence and does not
extend the assignment made in Section (e) below.
(d) During the term of my employment and for one (1) year thereafter, I
will not encourage or solicit any employee of the Company to leave the Company
for any reason or to devote less than all of any such employee's efforts to the
affairs of the Company, provided that the foregoing shall not affect any
responsibility I may have as an employee of the Company with respect to the bona
fide hiring and firing of Company personnel.
(e) I agree that all inventions which I make, conceive, reduce to practice
or develop (in whole or in part, either alone or jointly with others) during my
employment shall be the sole property of the Company to the maximum extent
permitted by Section 2870 of the California Labor Code, a copy of which is
attached herewith, and to the extent permitted by law shall be "works made for
hire." The Company shall be the sole owner of all patents, copyrights, trade
secret rights, and other intellectual property or other rights in connection
therewith. I hereby assign to the Company any rights I may have or acquire in
such Inventions. I agree to perform, during and after my employment, all acts
deemed necessary or desirable by the Company to permit and assist it, at the
Company's expense, in obtaining and enforcing patents, copyrights, trade secret
rights or other rights on such inventions and/or any other inventions I have or
may at any time assign to the Company in any and all countries. Such acts may
include, but are not limited to, execution of documents and assistance or
cooperation in legal proceedings. With respect to any and all matters arising
out of or relating to my employment or consultancy with the Company, I hereby
irrevocably designate and appoint the Company and its duly authorized officers
and agents, as my agents and attorneys-in-fact to act for and in my behalf and
instead of me, to execute and file any applications or related filings and to do
all other lawfully permitted acts to further the prosecution and issuance of
patents, copyrights, trade secret rights or other rights thereon with the same
legal force and effect as if executed by me.
(f) I attach hereto a complete list of all inventions or improvements to
which I claim ownership and/or that I desire to remove from the operation of
this Agreement, and I covenant that such list is complete. If no such list is
attached to this Agreement, I represent that I have no such inventions and
improvements at the time of signing this Agreement. I understand that any such
list shall not contain information that breaches an obligation of
confidentiality with a former employer.
<PAGE>
Peter J. Langecker, M.D., Ph.D.
3 September 1999
Page 9
(g) I represent that my performance of all the terms of this Agreement
will not breach any agreement or obligation to keep in confidence proprietary
information acquired by me in confidence or in trust prior to my employment by
the Company. I have not entered into, and I agree I will not enter into, any
agreement either written or oral in conflict herewith or in conflict with my
employment with the Company.
3. In consideration of the foregoing, the Company agrees that it will not
request as part of my employment that I divulge or make use of confidential
information of any of my former employers that has commercial value to the
former employer who developed such information.
4. This Agreement shall be effective as of the first day of my employment by
the Company, and shall be binding upon me, my heirs, executors, assigns, and
administrators and shall inure to the benefit of the Company, its subsidiaries,
successors and assigns.
Accepted and Agreed to:
Dated: September 4, 1999
---------------------------
/s/ Peter J. Langecker, M.D. By: /s/ Mark Moran
--------------------------------- ---------------------------
Peter J. Langecker, M.D., Ph.D. Mark Moran, M.D.
Chief Executive Officer
BioMedicines, Inc.
<PAGE>
Peter J. Langecker, M.D., Ph.D.
3 September 1999
Page 10
EXHIBIT A
1. The following is a complete list of all inventions or improvements
relevant to the subject matter of my employment by BioMedicines, Inc. (the
"Company") that have been made or conceived or first reduced to practice by me
alone or jointly with others prior to my employment by the Company that I desire
to remove from the operation of the Company's Proprietary Information and
Inventions Agreement.
X No inventions or improvements.
---
2. I propose to bring to my employment the following materials and documents
of a former employer:
X No materials or documents.
---
/s/ Peter J. Langecker, M.D.
-------------------------------------
Peter J. Langecker, M.D., Ph.D.
<PAGE>
Peter J. Langecker, M.D., Ph.D.
3 September 1999
Page 11
EXHIBIT B
SECTION 2870. APPLICATION OF PROVISION PROVIDING THAT EMPLOYEE SHALL ASSIGN
OR OFFER TO ASSIGN RIGHTS IN INVENTION TO EMPLOYER.
(a) Any provision in an employment agreement which provides that an employee
shall assign, or offer to assign, any of his or her rights in an invention to
his or her employer shall not apply to an invention that the employee developed
entirely on his or her own time without using the employer's equipment,
supplies, facilities, or trade secret information except for those inventions
that either:
(1) Relate at the time of conception or reduction to practice of the
invention to the employer's business, or actual or demonstrably anticipated
research or development of the employer.
(2) Result from any work performed by the employee for the employer.
(b) To the extent a provision in an employment agreement purports to require an
employee to assign an invention otherwise excluded from being required to be
assigned under subdivision (a), the provision is against the public policy of
this state and is unenforceable.